Strengths and weaknesses of FDA-approved/cleared diagnostic devices for the molecular detection of respiratory pathogens
- PMID: 21460290
- PMCID: PMC7107808
- DOI: 10.1093/cid/cir046
Strengths and weaknesses of FDA-approved/cleared diagnostic devices for the molecular detection of respiratory pathogens
Abstract
The rapid, sensitive, and specific identification of the microbial etiological characteristics of respiratory tract infections enhances the appropriate use of both antibiotics and antiviral agents and reduces the risk of nosocomial transmission. This article reviews the current nucleic acid amplification tests approved by the U.S. Food and Drug Administration (FDA) for the detection of respiratory pathogens. In addition, Emergency Use Authorization tests for the detection of 2009 influenza A H1N1 are discussed. The advantages and limitations of the current FDA-approved/cleared tests are reviewed.
Figures
References
-
- Paterson DL. The role of antimicrobial management programs in optimizing antibiotic prescribing within hospitals. Clin Infect Dis. 2006;42:S90–5. - PubMed
-
- Gonzales R, Malone DC, Maselli JH, Sande MA. Excessive antibiotic use for acute respiratory infections in the United States. Clin Infect Dis. 2001;33:757–62. - PubMed
-
- Casiano-Colon AE, Hulbert BB, Mayer TK, Walsh EE, Falsey AR. Lack of sensitivity of rapid antigen tests for the diagnosis of respiratory syncytial virus infection in adults. J Clin Virol. 2003;28:169–74. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
